173 related articles for article (PubMed ID: 26126205)
1. Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG).
de Laat JM; Dekkers OM; Pieterman CR; Kluijfhout WP; Hermus AR; Pereira AM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; de Herder WW; Valk GD
J Clin Endocrinol Metab; 2015 Sep; 100(9):3288-96. PubMed ID: 26126205
[TBL] [Abstract][Full Text] [Related]
2. Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China.
Wu Y; Gao L; Guo X; Wang Z; Lian W; Deng K; Lu L; Xing B; Zhu H
Pituitary; 2019 Apr; 22(2):113-123. PubMed ID: 30637623
[TBL] [Abstract][Full Text] [Related]
3. Traits of Patients With Pituitary Tumors in Multiple Endocrine Neoplasia Type 1 and Comparing Different Mutation Status.
Lin KY; Kuo YT; Cheng MF; Chen PL; Wang HP; Cheng TY; Chang CH; Kao HF; Yang SH; Li HY; Lin CH; Chou YT; Chung AK; Wu WC; Lu JY; Wang CY; Hsih WH; Wen CY; Yang WS; Shih SR
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1532-e1541. PubMed ID: 37390813
[TBL] [Abstract][Full Text] [Related]
4. Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience.
Cohen-Cohen S; Brown DA; Himes BT; Wheeler LP; Ruff MW; Major BT; Singh Ospina NM; Atkinson JLD; Meyer FB; Bancos I; Young WF; Van Gompel JJ
J Neurosurg; 2020 Apr; 134(3):1132-1138. PubMed ID: 32244213
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
6. Transdifferentiation of Neuroendocrine Cells: Gangliocytoma Associated With Two Pituitary Adenomas of Different Lineage in MEN1.
Sergeant C; Jublanc C; Leclercq D; Boch AL; Bielle F; Raverot G; Daly AF; Trouillas J; Villa C
Am J Surg Pathol; 2017 Jun; 41(6):849-853. PubMed ID: 28079577
[TBL] [Abstract][Full Text] [Related]
7. Clinical characterization of familial isolated pituitary adenomas.
Daly AF; Jaffrain-Rea ML; Ciccarelli A; Valdes-Socin H; Rohmer V; Tamburrano G; Borson-Chazot C; Estour B; Ciccarelli E; Brue T; Ferolla P; Emy P; Colao A; De Menis E; Lecomte P; Penfornis F; Delemer B; Bertherat J; Wémeau JL; De Herder W; Archambeaud F; Stevenaert A; Calender A; Murat A; Cavagnini F; Beckers A
J Clin Endocrinol Metab; 2006 Sep; 91(9):3316-23. PubMed ID: 16787992
[TBL] [Abstract][Full Text] [Related]
8. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma.
Hao W; Skarulis MC; Simonds WF; Weinstein LS; Agarwal SK; Mateo C; James-Newton L; Hobbs GR; Gibril F; Jensen RT; Marx SJ
J Clin Endocrinol Metab; 2004 Aug; 89(8):3776-84. PubMed ID: 15292304
[TBL] [Abstract][Full Text] [Related]
9. What is the natural history of nonoperated nonfunctioning pituitary adenomas?
Karavitaki N; Collison K; Halliday J; Byrne JV; Price P; Cudlip S; Wass JA
Clin Endocrinol (Oxf); 2007 Dec; 67(6):938-43. PubMed ID: 17692109
[TBL] [Abstract][Full Text] [Related]
10. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
Vergès B; Boureille F; Goudet P; Murat A; Beckers A; Sassolas G; Cougard P; Chambe B; Montvernay C; Calender A
J Clin Endocrinol Metab; 2002 Feb; 87(2):457-65. PubMed ID: 11836268
[TBL] [Abstract][Full Text] [Related]
11. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.
Cazabat L; Bouligand J; Salenave S; Bernier M; Gaillard S; Parker F; Young J; Guiochon-Mantel A; Chanson P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E663-70. PubMed ID: 22319033
[TBL] [Abstract][Full Text] [Related]
12. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
13. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome.
Pieterman CR; Schreinemakers JM; Koppeschaar HP; Vriens MR; Rinkes IH; Zonnenberg BA; van der Luijt RB; Valk GD
Clin Endocrinol (Oxf); 2009 Apr; 70(4):575-81. PubMed ID: 18616711
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study.
Le Bras M; Leclerc H; Rousseau O; Goudet P; Cuny T; Castinetti F; Bauters C; Chanson P; Tabarin A; Gaujoux S; Christin-Maitre S; Ruszniewski P; Borson-Chazot F; Guilhem I; Caron P; Goichot B; Beckers A; Delemer B; Raingeard I; Vergès B; Smati S; Wargny M; Cariou B; Hadjadj S
Eur J Endocrinol; 2021 Nov; 185(6):863-873. PubMed ID: 34636744
[TBL] [Abstract][Full Text] [Related]
15. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.
Korsisaari N; Ross J; Wu X; Kowanetz M; Pal N; Hall L; Eastham-Anderson J; Forrest WF; Van Bruggen N; Peale FV; Ferrara N
Clin Cancer Res; 2008 Jan; 14(1):249-58. PubMed ID: 18172277
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred.
Burgess JR; Shepherd JJ; Parameswaran V; Hoffman L; Greenaway TM
J Clin Endocrinol Metab; 1996 Jul; 81(7):2642-6. PubMed ID: 8675591
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
[TBL] [Abstract][Full Text] [Related]
18. MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors.
Vannucci L; Marini F; Giusti F; Ciuffi S; Tonelli F; Brandi ML
Endocrine; 2018 Feb; 59(2):438-448. PubMed ID: 28530019
[TBL] [Abstract][Full Text] [Related]
19. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients.
de Laat JM; Pieterman CR; van den Broek MF; Twisk JW; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2014 Sep; 99(9):3325-33. PubMed ID: 24915123
[TBL] [Abstract][Full Text] [Related]
20. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines.
Goudet P; Dalac A; Le Bras M; Cardot-Bauters C; Niccoli P; Lévy-Bohbot N; du Boullay H; Bertagna X; Ruszniewski P; Borson-Chazot F; Vergès B; Sadoul JL; Ménégaux F; Tabarin A; Kühn JM; d'Anella P; Chabre O; Christin-Maitre S; Cadiot G; Binquet C; Delemer B
J Clin Endocrinol Metab; 2015 Apr; 100(4):1568-77. PubMed ID: 25594862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
